E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Qilu will supply IV pembrolizumab biosimilar to Orion Pharma and will be entitled to receive a share of the profits generated by Orion Pharma, as well as certain development, regulatory and sales milestone payments.
imphoenix82
A 65-year-old woman underwent a modified radical mastectomy, prosthetic aortic valve replacement and single-vessel coronary artery bypass grafting in a rare six-hour surgery that successfully treated breast cancer and two life-threatening heart conditions.
imphoenix82
The Tang Prize 2026 recognises three leading scientists in the field of cellular immunotherapy “for the discovery and development of TIL and CAR-T therapies, which have revolutionized treatment for blood cancers and solid tumours.”
imphoenix82
The targeted radioligand therapy Pluvicto will initially be available through selected hospitals and nuclear medicine centres across India under Novartis’ partnership-led access model.
imphoenix82
The NMPA clearance allows Adcentrx to include China-based clinical centres in its ongoing Phase 1a/1b trial evaluating the ADC in patients with late-stage solid tumours, including prostate cancer.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
